预约演示

更新于：2025-05-26

Epoprostenol Sodium

依前列醇钠

更新于：2025-05-26

概要

基本信息

药物类型

小分子化药

别名

(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate、(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid、Caripul

+ [21]

靶点

PGI2 receptor

作用方式

激动剂、抑制剂

作用机制

PGI2 receptor激动剂(前列腺素IP受体激动剂)、血小板聚集抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Actelion Pharmaceuticals Ltd.Actelion Pharmaceuticals US, Inc.GlaxoSmithKline LLC

+ [3]

非在研机构

Aerogen Pharma Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1995-09-20),

肺性高血压

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C20H32NaO5

InChIKeyWHVPOEPABJZBBY-XQYLJSSYSA-N

CAS号61849-14-7

关联

项与依前列醇钠相关的临床试验

NCT05450328

/ Not yet recruiting临床2期IIT

Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial

In cardiac surgery, the presence of pulmonary hypertension (PH) is a prognostic factor associated with increased mortality and morbidity. In this context, one of the main causes of PH is related to reperfusion ischemia during weaning from extracorporeal circulation (CPB). One of the consequences of PH is right ventricular dysfunction. During weaning from CPB, the development of a right ventricular dysfunction is associated with increased requirements for vasopressor and inotropic agents, duration of mechanical ventilation, prolonged intensive care and hospital stay, and increased mortality compared with patients with left ventricular (LV) dysfunction. The management of patients with PH with or without right ventricular (RV) dysfunction relies on several strategies such as the administration of intravenous and inhaled agents, or mechanical ventricular support. Among those agents, the administration of inotropes or pulmonary vasodilators such as epoprostenol, milrinone and nitric oxide are among the most widely used treatments recommended by the Canadian Cardiovascular Society. At the Montreal Heart Institute, inhaled epoprostenol and milrinone are routinely administered to patients with PH or LV dysfunction in the perioperative setting. Despite the frequent use of inhaled epoprostenol and milrinone, Health Canada has not yet approved the use of these molecules.
The primary objective of this multicenter, double-blind, randomized clinical trial is to evaluate the clinical efficacy of the combined administration of inhaled epoprostenol and milrinone in a cardiac surgery setting. This trial will compare the clinical outcome of 71 patients who will receive inhaled epoprostenol and milrinone before the start of bypass surgery to 71 patients who will receive a placebo before the start of the CPB. The primary clinical outcome is the proportion of patients with an "unsuccessful" CPB weaning defined by the use of an inotrope +/- vasopressor agent or the use of mechanical circulatory support or a return to bypass grafting for hemodynamic reasons.
This clinical trial will evaluate the clinical efficacy of the combination of inhaled agents in a cardiac surgery setting. Therefore, if the results of this study are positive, the combination of inhaled epoprostenol and milrinone will optimize the management of patients with pulmonary hypertension with or without a right ventricular dysfunction.

开始日期2024-06-01

申办/合作机构

Montréal Heart Institute

EUCTR2022-004079-17-DK

/ Not yet recruiting临床2期IIT

Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy– a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial - COMBAT-ARF

开始日期2023-03-20

申办/合作机构

Rigshospitalet

NCT04231084

/ Completed临床4期IIT

Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

开始日期2021-01-15

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与依前列醇钠相关的临床结果

登录后查看更多信息

100 项与依前列醇钠相关的转化医学

登录后查看更多信息

100 项与依前列醇钠相关的专利（医药）

登录后查看更多信息

18,772

项与依前列醇钠相关的文献（医药）

2025-07-01·BIOCHIMIE

Human prostacyclin and thromboxane synthases: Molecular interactions, regulation, and pharmacology

Review

作者: Mezentsev, Yuri V ; Ivanov, Alexis S ; Ershov, Pavel V ; Yablokov, Evgeniy O

Prostanoids are lipid mediators of the human body that are involved in the inflammation and platelet aggregation. Prostacyclin is a vasodilator and inhibitor of platelet aggregation, and a product of the enzymatic reaction catalyzed by prostacyclin synthase (PTGIS). Thromboxane is a vasoconstrictor and synthesized by thromboxane synthase (TBXAS1). An imbalance of prostanoids can accompany cardio-/cerebrovascular diseases and cancers. PTGIS and TBXAS1 are clinically relevant membrane-bound enzymes of the multigene family of cytochromes P450 (CYPs), also known as CYP8A1 and CYP5A1, respectively. Particular studies of these functional antagonists will contribute to the elucidation of pathogenic mechanisms. The purpose of this work was to analyze the literature landscape over a period of 2020-2024 in the field of biological, pharmacogenomic, and pharmacological features of PTGIS and TBXAS1 as well as to explore the potential of their regulation at the post-transcriptional and post-translational levels using systems biological analysis. The review discusses recent findings on the novel aspects of both synthases established in gene knockout and overexpression experiments, current preclinical pharmacology, and potential ways of gene expression regulation. Identification of protein-protein interactions and post-translational modifications appear to be the main options for modulating PTGIS and TBXAS1 activity. The microsomal CYPs are known to form complexes with each other and direct interactions of CYP2E1 with both synthases can probably lead to modulation of their activity. Progress in the preclinical development of low molecular weight compounds as inhibitors of TBXAS1 is more prospective than PTGIS that is applied as gene therapy biologicals for in vivo production of prostacyclin due to its noticeable anticancer and vasodilator effects.

2025-06-01·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Low phylloquinone intake deteriorates endothelial function in normolipidemic and dyslipidaemic mice

Article

作者: Kus, Kamil ; Sternak, Magdalena ; Zeber-Lubecka, Natalia ; Zakrzewska, Agnieszka ; Przyborowski, Kamil ; Franczyk-Zarow, Magdalena ; Proniewski, Bartosz ; Princen, Hans M G ; Kulecka, Maria ; Mohaissen, Tasnim ; Strus, Magdalena ; Kwiatkowski, Grzegorz ; Kij, Agnieszka ; Bar, Anna ; Buczek, Elzbieta ; Czyzynska-Cichon, Izabela ; Kostogrys, Renata B ; Kozien, Lucja ; Chlopicki, Stefan ; Kieronska-Rudek, Anna ; Pieterman, Elsbeth J ; Wiecek, Grazyna

While the plasma phylloquinone (PK) concentration is inversely correlated with cardiovascular risk, the involvement of PK in regulating endothelial function has not been directly investigated. Therefore, in this study we assessed the effects of short-term treatment with PK-deficient diets (5-10 weeks) on endothelial function in normolipidemic 14-week-old male C57BL/6JCmd mice and age-matched dyslipidaemic male E3L.CETP mice. Our results show that in normolipidemic mice dietary PK deficiency was associated with a marked reduction of PK levels in the plasma and liver (liquid chromatography-mass spectrometry measurements) and with impaired endothelium-dependent vasodilation assessed in vivo by magnetic resonance imaging (MRI). Dietary PK deficiency-induced endothelial dysfunction was fully reversed by PK supplementation. In dyslipidaemic E3L.CETP mice, dietary PK deficiency exacerbated preexisting endothelial dysfunction. Furthermore, dietary PK deficiency decreased menaquinone-4 (MK-4) levels in the aorta but did not affect blood coagulation (calibrated automated thrombography), microbiota composition (culturing and next-generation sequencing), and gut menaquinone production. In conclusion, our study demonstrated for the first time that sufficient dietary PK intake supports endothelial function in normolipidemic and dyslipidaemic mice indicating nutritional significance of dietary PK in the maintenance of endothelial function in humans.

2025-06-01·British Journal of Pharmacology

Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling

Article

作者: Wojciak‐Stothard, Beata ; Fellows, Adam L. ; Barnett, Harry ; Miller, David ; Leung, Venus ; Ainscough, Alexander J. ; Wilkins, Martin R. ; Quigley, Kate ; Mayr, Manuel

Abstract:

Background and Purpose:

Vasoreactivity of pulmonary arteries regulates blood flow through the lungs. Excessive constriction of these vessels contributes to pulmonary arterial hypertension (PAH), a progressive and incurable condition, resulting in right heart failure. The search for new and improved drug treatments is hampered by laboratory models that do not reproduce the vasoactive behaviour of healthy and diseased human arteries.

Experimental Approach:

We have developed an innovative technique for producing miniature, three‐dimensional arterial structures that allow proxy evaluation of human pulmonary artery contractility. These “engineered pulmonary artery tissues” or “EPATs” are fabricated by suspending human pulmonary artery vascular smooth muscle cells (VSMCs) in fibrin hydrogels between pairs of silicone posts, located on custom‐made racks, in 24‐well culture plates.

Key Results:

EPATs exhibit rapid, robust and reproducible contraction responses to vasoconstrictors (KCl, ET‐1, U46619) as well as relaxation responses to clinically approved PAH vasodilatory drugs that target several signalling pathways, such as bosentan, epoprostenol, selexipag and imatinib. EPATs composed of pulmonary artery VSMCs from PAH patients exhibit enhanced contraction to vasoconstrictors and relaxation in response to vasodilators. We also demonstrate the incorporation of endothelial cells into EPATs for the measurement of endothelium‐dependent dilatory responses.

Conclusion and Implications:

We demonstrate the capacity and suitability of EPATs for studying the contractile behaviour of human arterial cells and preclinical drug testing. This novel biomimetic platform has the potential to dramatically improve our understanding and treatment of cardiovascular disease.

项与依前列醇钠相关的新闻（医药）

2025-05-23

·cerenoscientific.com

Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH)

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the US Food & Drug Administration (FDA) provided endorsement of the plans for the Phase IIb trial of CS1 as noted by the official meeting minutes from the Type C-meeting held on April 21. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial aiming to further evaluate the encouraging efficacy signs including reverse vascular remodeling and improvement of right heart function as observed in the Phase IIa trial. “This is a very exciting milestone for our pipeline. Receiving an FDA endorsement for the CS1 program in PAH at this stage in development is paving the way for further interactions regarding upcoming Phase IIb and pivotal Phase III trials. The plans for the Phase IIb trial are in alignment with the expectations of the FDA, meaning that we have high confidence that the Phase IIb trial design will include the relevant criteria contributing to the development program’s marketing approval process. We are now continuing steps for preparations ahead of the Phase IIb trial in PAH, with a target of initiating the trial in H1 2026,” said Rahul Agrawal, Chief Medical Officer (CMO) and Head of R&D at Cereno Scientific. “The endorsement from the FDA for CS1 validates that the development plans have sound rationale to be able to support documentation for future marketing approval and adds credibility to our scientific and clinical capabilities. These are important factors in the dialogues we have with potential partners, but also other stakeholders we interact with such as collaborators, investors and the scientific community. We are keen to progress towards the initiation of the Phase IIb trial to further evaluate CS1 as a PAH treatment with favorable safety and tolerability and disease-modifying capacity. Our ultimate ambition is to be able to develop a treatment that could enhance and extend life of patients suffering from this devastating and fatal disease,” said Sörensen, CEO at Cereno Scientific. Drug candidate CS1 is a well-tolerated oral therapy with a favorable safety profile and showed signals of disease-modifying effects as observed in a Phase IIa trial in patients with the rare disease pulmonary arterial hypertension (PAH). The aim for CS1 is to offer an effective disease-modifying treatment with the ability to enhance quality of life and extend life for PAH patients. Unlike standard therapy that focus on managing symptoms, CS1 represents a novel therapeutic approach by targeting the root mechanisms of PAH. Specifically, CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries. A successful Phase IIa trial was concluded in 2024. Insights into the long-term use of CS1 are being gathered in an expanded access program with 10 patients from the Phase IIa trial. Preparations are currently underway for a larger placebo-controlled Phase IIb trial to continue advancing CS1 toward regulatory approval and wider patient access. The Phase IIb trial is planned to be initiated in H1 2026. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床2期临床1期

2025-05-17

·梅斯医学

一运动就气喘不已，误以为是体弱，医生却告诉他患上了心血管系统的癌症，误诊率高达90%

21岁的小王，从小就是大家眼里的“体弱生”——不爱运动，走路慢，爬楼梯总是落在最后。小学体育课他跑不过女生，初中篮球赛常常还没上场就已经喘得满脸通红。老师觉得他“娇气”，同学以为他“懒”，连家人也只是当他“锻炼太少”。“我真不是不想跑，我是真的跑不动。”小王总是这样解释，但没人相信。直到上大学军训，他因为短短的五分钟小跑突然脸色苍白、呼吸困难，甚至差点晕倒，被紧急送医。医生听诊发现他心音异常，进一步检查中血氧偏低、心电图提示右心负荷过重，心脏超声也显示右心扩大。肺部CT正常，但超声心动图提示肺动脉收缩压升高，右心导管检查证实：小王患上的是一种罕见而严重的心肺疾病——特发性肺动脉高压（IPAH）。特发性肺动脉高压特发性肺动脉高压（idiopathic pulmonary arterial hypertension，IPAH）指一类无明确原因、以肺血管阻力进行性升高为主要特征的恶性肺血管疾病，不伴随任何可能导致该种情况的基础疾病，患者往往合并不同程度右心功能衰竭甚至死亡。欧美注册登记研究结果表明，平均诊断年龄为50～65岁.男女发病率为1:2～3。欧洲资料显示,成年人特发性肺动脉高压的患病率约为5.9/100万。我国缺乏特发性肺动脉高压流行病学数据，患者以中青年女性为主，平均诊断年龄约为36岁。我国学者研究表明，仅接受传统药物治疗，特发性肺动脉高压与家族性肺动脉高压患者1年、3年、5年的生存率分别为68%、38.9%、20.8%。临床表现原发性肺动脉高压（IPAH）的临床表现与其他类型的肺动脉高压相似，症状和体征缺乏特异性。最常见的症状是活动后气短，此外还可出现乏力、头晕、胸痛、胸闷、心悸、黑矇和晕厥等。特别是当出现晕厥或眩晕时，提示患者的心搏量可能已明显下降，病情较为严重。由于缺乏特异性的症状和体征，绝大多数患者的就诊存在明显延迟。研究显示，至少有五分之一的患者从症状出现到确诊的时间超过两年；超过一半的IPAH患者在确诊时已处于WHO功能分级的Ⅲ～Ⅳ级阶段，提示病情在确诊时往往已较为严重。IPAH的体征主要与肺动脉压力升高和右心衰竭有关。肺动脉压力升高时，可听到肺动脉瓣第二心音亢进，三尖瓣关闭不全可引起三尖瓣区的收缩期杂音。右心衰竭的体征则包括颈静脉充盈或怒张、肝脏肿大、下肢水肿、多浆膜腔积液，以及在晚期可能出现的黄疸和发绀等表现。诊断IPAH的初步检查包括血常规、心电图、X线等，可提示肺动脉高压迹象。进一步评估需进行血气分析、肺功能、CT、超声心动图、右心导管检查等。血液检查中，血红蛋白常因缺氧升高，脑钠肽水平升高提示病情加重。血气分析多见低氧血症，二氧化碳分压下降。影像学方面，X线可见肺动脉增粗，CT用于排查肺间质病变和肺血管畸形，核素肺通气/灌注显像在筛查慢性肺血栓性疾病中较敏感。超声心动图可评估肺动脉压和右心功能，是常用筛查手段。右心导管检查是诊断IPAH的金标准。静息时平均肺动脉压≥25 mmHg、肺动脉楔压≤15 mmHg、肺血管阻力＞3 Wood单位可确诊。检查时应排除其他引起肺高压的病因，如心肺疾病、结缔组织病、药物或毒物暴露等。诊断需结合病史、临床表现和多项检查结果，遵循标准流程，排除继发性肺动脉高压，方可确诊IPAH。治疗IPAH是一种进展性、不可逆的疾病，目前尚无法根治。治疗目标主要是降低肺循环阻力，改善右心功能、提升运动耐量和延长生存期。治疗可分为三大方面：一般治疗包括指导适度体力活动和康复训练、避免妊娠、预防感染、提供心理和社会支持、加强依从性管理，以及必要的遗传咨询。同时建议使用华法林抗凝，并在条件允许时转诊至专业的肺动脉高压中心。药物治疗前需通过右心导管检查进行风险评估及急性血管扩张试验，选择个体化药物方案。急性扩张试验阳性的患者可使用高剂量钙通道阻滞剂。其余常用靶向药物包括磷酸二酯酶-5抑制剂（如西地那非、他达拉非）、内皮素受体拮抗剂（如波生坦、安立生坦、马西替坦）、前列环素类药物（如伊洛前列素、瑞莫杜林）、可溶性鸟苷酸环化酶激动剂（如利奥西呱）和前列环素受体激动剂赛乐西帕。手术治疗适用于病情严重、药物无效的患者。球囊扩张房间隔造口术可作为姑息性治疗或肺移植前的过渡措施。肺移植或心肺联合移植虽风险较高，但目前是唯一可能实现根治的治疗方式。参考资料：[1]中华医学会呼吸病学分会肺栓塞与中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血病防治协作组，等.中国肺动脉高压诊华医学杂志，2021，101(1):11-51[2]Hassoun P M, Taichman D B. Pulmonary Arterial Hypertension[J]. New England J Med, 2021, 385(25):2361-2376.[3]Humbert M, Kovacs G, Hoeper M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38):3618-3731.来源 | 梅斯医学编辑 | wanny神经系统罕见病交流群↓点击下方“阅读原文”，下载梅斯医学APP吧！

2025-05-13

·cerenoscientific.com

Cereno Scientific presented CS1’s Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that an oral presentation titled “Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial” was presented at the 5th Baltic Pulmonary Hypertension Conference 2025 on May 9, 2025, in Kaunas, Lithuania. The data presented in an abstract at the Baltic PH Conference highlighted key results from the Phase IIa trial of CS1 in PAH. The primary endpoint of safety and tolerability was met without any drug-related safety concerns. After 12 weeks, REVEAL Risk Score 2.0 was improved from baseline in 40.9% of patients and stable in a further 31.8% of patients. A total of 31.8% and 54.5% of patients improved or maintained their NYHA/WHO functional class, respectively. The majority of patients (71%) showed an improvement in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The abstract concludes that the findings from the Phase IIa trial suggest that treatment with CS1 in patients with pulmonary arterial hypertension (PAH) improve risk score, functional class and quality of life. The conclusion states that CS1 warrants further study. Tatiane Abreu Dall’Agnol, Medical Director at Cereno Scientific, presented the abstract at the conference. “I am pleased that we have now presented the results from our Phase IIa trial of CS1 in PAH to the scientific community in a formal setting. The Phase IIa trial demonstrated that CS1 is well-tolerated and has a favorable safety profile. Importantly, we observed encouraging signals of reverse vascular remodeling. These exploratory efficacy findings are promising and we are now planning a larger, placebo-controlled Phase IIb trial in PAH to further evaluate these effects,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. “There remains a profound unmet need in PAH for treatments that do more than just manage symptoms. With CS1, we are developing a potential first-in-class, disease-modifying therapy that targets the root mechanisms driving PAH — pathological vascular remodeling and right heart dysfunction. The favorable safety and tolerability profile, along with encouraging efficacy signals observed in our clinical development to date, reinforce CS1’s potential to transform how PAH is treated. We are proud to continue advancing this innovation with the goal of meaningfully improving the lives of patients living with this devastating disease,” said Sten R. Sörensen, CEO of Cereno Scientific. A publication of the Phase IIa trial results of CS1 in PAH is in development with the aim be published during H2 2025. Abstract details: Benza, R., et al. (2025). Exploratory outcomes of CS1 in pulmonary arterial hypertension: Phase 2A, prospective, randomized, open-label, multicenter trial Raymond [Abstract]. Abstracts book of the 5th Baltic Pulmonary Hypertension Conference 2025, Kaunas, Lithuania. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床2期临床结果临床1期

100 项与依前列醇钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01337	依前列醇钠	B01AC09	DB01240

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺动脉高压	日本	GlaxoSmithKline KK	1999-01-25
肺性高血压	美国	GlaxoSmithKline LLC	1995-09-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性肺动脉高压	临床3期	比利时	Actelion Pharmaceuticals US, Inc.	2011-03-01
家族性肺动脉高压	临床3期	加拿大	Actelion Pharmaceuticals US, Inc.	2011-03-01
家族性肺动脉高压	临床3期	法国	Actelion Pharmaceuticals US, Inc.	2011-03-01
家族性肺动脉高压	临床3期	意大利	Actelion Pharmaceuticals US, Inc.	2011-03-01
家族性肺动脉高压	临床3期	荷兰	Actelion Pharmaceuticals US, Inc.	2011-03-01
家族性肺动脉高压	临床3期	西班牙	Actelion Pharmaceuticals US, Inc.	2011-03-01
新型冠状病毒感染	临床2期	美国	Aerogen Pharma Ltd.	2020-09-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02251041 (CAPITL, CTgov)	临床2期	再灌注损伤	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	壓膚蓋遞鹹衊製遞製襯 = 艱觸選顧遞鏇鹽壓衊齋鏇壓觸襯簾壓齋鏇顧遞 (夢選網壓醖膚鏇獵選範, 願夢壓觸餘餘餘餘壓願 ~ 遞製鑰襯膚顧艱膚淵製) 更多	-	2024-08-23
ATS2024	N/A	肺动脉高压	-	Intravenous prostacyclin (epoprostenol or treprostinil)	糧醖衊衊鑰窪鬱醖壓窪(鑰鏇積鑰鑰獵獵獵衊襯) = 夢襯繭獵艱獵憲廠醖積壓淵壓構製壓網選艱膚 (鬱鹹觸鑰鹹憲製壓網廠, 307) 更多	-	2024-05-19
				Oral prostacyclin	糧醖衊衊鑰窪鬱醖壓窪(鑰鏇積鑰鑰獵獵獵衊襯) = 窪獵壓製鑰壓鬱鹹網獵壓淵壓構製壓網選艱膚 (鬱鹹觸鑰鹹憲製壓網廠, 47.2)
ATS2024	N/A	心脏衰竭	-	Epoprostenol	鏇顧願遞鑰鏇餘齋鑰構(網積構夢遞醖壓鹽夢夢) = 鏇簾廠齋醖鏇憲築鹹窪獵鑰顧鏇鬱醖膚衊簾衊 (壓範膚製顧鑰築鹹鏇製 ) 更多	-	2024-05-19
NCT03081052 (Pubmed)	临床4期	-	231	Inhaled Epoprostenol	積衊鹽糧憲遞廠構觸構(窪鑰衊壓鬱蓋獵醖膚蓋) = 夢艱築願膚蓋廠鹹壓衊齋艱顧醖襯鑰廠觸獵襯 (餘繭餘構憲齋夢艱鹹鹽 )	-	2023-07-04
				Nitric Oxide	積衊鹽糧憲遞廠構觸構(窪鑰衊壓鬱蓋獵醖膚蓋) = 簾壓蓋網鑰衊繭膚鬱網齋艱顧醖襯鑰廠觸獵襯 (餘繭餘構憲齋夢艱鹹鹽 )
PSAT054 (ENDO2022)	N/A	孤立性ACTH缺乏症	-	Epoprostenol	範願獵憲衊觸觸衊鹽淵(窪顧願範襯齋襯選鏇鏇) = 鑰遞蓋鹹窪壓選廠願鬱製鏇繭壓願鏇廠簾餘憲 (鬱衊網襯廠憲鹹糧製鏇 )	-	2022-11-01
ATS2022	N/A	新型冠状病毒感染	-	HFNC+iEPO	願築網夢壓獵範夢憲願(壓艱衊齋夢獵夢鏇醖齋) = 鏇繭構鹽繭觸衊鹹餘鑰顧糧獵衊積齋遞膚醖廠 (遞齋餘鏇選願餘蓋壓憲 ) 更多	-	2022-05-15
				HFNC alone	憲顧獵鹹餘顧網艱齋鑰(網繭窪鏇顧壓簾鑰憲鏇) = 顧網範蓋壓範餘糧衊廠壓構鏇觸鏇憲衊糧積願 (網製觸壓壓夢鑰顧夢鬱 )
ATS2022	N/A	肺动脉高压	-	Self-admixed infused prostacyclins	觸襯夢遞憲鹹壓憲夢窪(廠壓糧壓鹹獵願醖觸鏇) = 壓膚顧鹽夢鬱願觸淵顧壓襯願顧壓淵艱鹹廠鑰 (築蓋鑰繭鏇憲襯遞繭鏇 )	-	2022-05-15
				Pharmacy-prepared admixture	觸襯夢遞憲鹹壓憲夢窪(廠壓糧壓鹹獵願醖觸鏇) = 製艱鑰夢衊憲鏇繭鬱襯壓襯願顧壓淵艱鹹廠鑰 (築蓋鑰繭鏇憲襯遞繭鏇 )
NCT03081052 (INSPIRE-FLO, CTgov)	临床4期	肺部疾病 \| 心脏衰竭 \| 器官移植排斥	519	iNO (Lung Transplant With iNO)	鑰艱簾糧淵選鑰繭壓鹹 = 蓋簾鏇齋鬱觸艱鹽獵艱鹹簾獵觸蓋積鬱遞構鹽 (壓廠憲壓淵築齋觸鏇遞, 觸鹽願製獵顧醖艱蓋窪 ~ 鏇選壓築選醖顧鑰網積) 更多	-	2022-03-10
				iEPO (Lung Transplant With iEPO)	鑰艱簾糧淵選鑰繭壓鹹 = 築鬱衊壓築網獵蓋窪製鹹簾獵觸蓋積鬱遞構鹽 (壓廠憲壓淵築齋觸鏇遞, 憲夢構繭鑰鹹壓鏇衊夢 ~ 淵衊獵顧願積壓簾夢襯) 更多
NCT01462565 (CTgov)	临床4期	肺动脉高压	16	Epoprostenol Sodium	夢觸鹽醖糧餘鹽繭遞繭(鏇顧繭蓋糧夢齋鬱鑰願) = 繭鹽鑰壓積齋廠窪製襯鏇壓願鹽鹹遞製醖廠鑰 (餘窪簾獵積獵網夢廠願, 3.6593) 更多	-	2017-10-16
NCT01717209 (CTgov)	临床4期	心脏衰竭	14	Nitric Oxide+Prostacyclin	餘構醖構醖糧淵簾膚膚(蓋鏇鏇簾襯遞觸醖壓鹹) = 製願網艱膚鑰廠選憲餘鏇壓構觸築淵製餘製淵 (窪網鑰積膚築繭鹹齋鬱, 壓製繭夢觸鏇製選範獵 ~ 獵範簾醖築鏇壓夢繭艱) 更多	-	2017-10-09